Company Analysis
Sign in

Galmed Pharmaceuticals Ltd. (GLMD)

Nasdaq: GLMD · Pharmaceutical Preparations · Ramat Gan, IL · filing with the SEC since 2013
Full chart Alerts Compare
Grade4.1
◀ Past 4.5● Present 5.6▶ Future 2.6
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2020, as filed
Revenue$0.00
Net income-$28.8M-240.5%
Earnings per share$16.20+39.2%
Operating cash flow-$26.3M-76.0%
Cash$6.9M-56.4%
Debtn/a
Shareholders’ equity$44.2M-36.8%
Shares, diluted1,773,399+0.8%
Return on equity43.7%
The recordfrom its filings
Filings in 202644
Newest filingNov 10 · 6-K
Annual reportMar 31, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted5
Filer categoryNon-accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Sep 3, 2026 · SEC EDGAR · Form EFFECT
Registration effective
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton GLMD · research, not advice